BELLUS Health to Present at Three Upcoming Healthcare Investor Conferences

Date : 05/15/2019 @ 12:00PM
Source : Business Wire
Stock : Bellus Health Inc. (BLU)
Quote : 1.98  0.09 (4.76%) @ 8:57PM

BELLUS Health to Present at Three Upcoming Healthcare Investor Conferences

BELLUS Health Inc. (TSX:BLU)
Historical Stock Chart

2 Months : From Apr 2019 to Jun 2019

Click Here for more BELLUS Health Inc. Charts.

BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, President and Chief Executive Officer of BELLUS Health, will present a corporate overview of the Company, including an update on its lead program BLU-5937 for the treatment of chronic cough, at three upcoming healthcare investor conferences.

Conference Presentation Details:

 

Event: UBS 2019 Global Healthcare Conference

Date/Time: Monday, May 20, 2019 at 3:30 p.m. EDT

Location: New York, NY

 

Event: Jefferies 2019 Healthcare Conference

Date/Time: Wednesday, June 5, 2019 at 3:30 p.m. EDT

Location: New York, NY

 

Event: Raymond James Life Sciences and MedTech Conference

Date/Time: Wednesday, June 19, 2019 at 8:35 a.m. EDT

Location: New York, NY

 

Live webcasts from the UBS, Jefferies and Raymond James conference presentations may be accessed on the Events and Presentations page under the Investors & News section of BELLUS Health's website at www.bellushealth.com. Following the events, archived webcasts and presentations will be available on the Company’s website.

About BELLUS Health (www.bellushealth.com)

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company's lead product candidate, BLU-5937, is being developed for the treatment of chronic cough. BLU-5937, a highly selective P2X3 antagonist, has the potential to be a best-in-class therapeutic for chronic cough patients who do not respond to current therapies. In addition to chronic cough, BLU-5937 may potentially have clinical benefit in other afferent hypersensitization-related disorders, such as visceral pain, hypertension, and migraine, among others. BELLUS Health is currently conducting pre-clinical studies in additional undisclosed indications.

Chronic cough is classified as a cough lasting more than eight weeks and is associated with significant adverse physical, social and psychosocial effects on health and quality-of-life. More than 26 million adults in the United States suffer from chronic cough. Of these patients, more than 2.6 million have unexplained or refractory chronic cough lasting for more than a year. There are currently no approved treatments for refractory chronic cough, creating a significant unmet medical need.

Investors:BELLUS HealthFrançois DesjardinsVice-President, Finance450-680-4525fdesjardins@bellushealth.com

Solebury TroutChad Rubin646-378-2947crubin@soleburytrout.com

Media:Solebury TroutBrad Miles646-513-3125bmiles@soleburytrout.com

Latest TSX:BLU Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.